Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
GenSight Biologics
Biotech
GenSight enters final weeks of cash runway
GenSight has enough cash to fund operations into mid-November and, with a revenue stream set to start later than planned, needs financing to survive.
Nick Paul Taylor
Oct 25, 2024 3:19am
GenSight seeks cash as gene therapy runway enters final year
Apr 8, 2022 7:50am
Mutation-agnostic gene therapy triggers partial vision recovery
May 25, 2021 8:10am
EuroBiotech: More Articles of Note
Apr 18, 2019 10:40am
GenSight’s vision loss gene therapy again fails in phase 3
Feb 4, 2019 6:26am
GenSight rebuilds its case for LHON gene therapy
Dec 12, 2018 9:29am
